China Resources Pharmaceutical Group (3320) H1 2026 earnings summary

Executive summary

• Revenue rose 2.0% year-over-year to RMB134,457.6 million for the six months ended 30 June 2026, with net profit at RMB5,023.5 million, down 0.6% year-over-year.

• Gross profit was RMB21,534.1 million, up 0.1% year-over-year, with a gross margin of 16.0%, down 0.3 percentage points.

• Interim dividend declared at RMB0.087 per share, a 21% increase year-over-year.

• The group maintained leading positions in pharmaceutical manufacturing and distribution, with strategic focus on R&D, digital transformation, and ESG.

Financial highlights

• Revenue: RMB134,457.6 million (+2.0% YoY); Gross profit: RMB21,534.1 million (+0.1% YoY).

• Net profit: RMB5,023.5 million (-0.6% YoY); Profit attributable to shareholders: RMB2,186.6 million (+5.3% YoY).

• Basic EPS: RMB0.35 (vs. RMB0.33 prior year); Interim dividend: RMB0.087/share (vs. RMB0.072 prior year).

• Gross margin: 16.0% (down 0.3 ppt YoY); Net cash from operating activities: RMB1,423.1 million.

Outlook and guidance

• Focus on strategic emerging industries: biological drugs, blood products, high-end medical devices, synthetic biology.

• Continued investment in R&D, digital transformation, and ESG initiatives.

• Plans to strengthen operational excellence, smart manufacturing, and international expansion.